

**Library & Information Services**

**Journal Club Checklist**

|  |  |
| --- | --- |
| **Title** | **Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumours with tigilanol tiglate (EBC-46) *Journal of Veterinary Internal Medicine*** |
| **What are the aims or objectives of the study?** |  |
| **Who carried out the research?** |  |
| **Is there a clear research question or hypothesis?**  Can the PICO be identified?  Is the control group appropriate? |  |
| **What methods did the researchers use?** |  |
| **Were personnel blinded to treatment?** |  |
| **Is this methodology appropriate to the objectives or question?** |  |
| **Is the study design described clearly enough to enable you to follow what was done?** |  |
| **Are the type of patients clearly described?**  **What were the Inclusion and exclusion criteria for participation?** |  |
|  |  |
| **Are these patients or participants, relevant to your practice, if not what differences need to be considered?** |  |
| **How many patients or participants were included in the study?** |  |
| **Were the patients divided into groups, if so, how was this done?** |  |
| **Were the groups similar at the start of the trial?** |  |
| **Is the data collected clearly described?** |  |
| **Are all patients or participants accounted for in the analysis?** |  |
| **Are the results of the study clearly described?** |  |
| **Were all clinically relevant outcomes considered?** |  |
| **What are the findings of the study?** |  |
| **Are the findings likely to be clinically, as well as statistically significant?** |  |
| **Limitations of the study** |  |
| **Do you think that there are any potential sources of bias in the paper?** |  |
| **How do the outcomes and adverse events reported compare with current (surgical) treatment methods?** |  |
| **Do the findings support or alter your current knowledge?** |  |
| **Do the findings provide sufficient evidence for you to consider**  **changing your current practice?** |  |
| **Are there any other sources of information you need to look at before using this product?** |  |

**\***   
The staging of mast cell tumours referred to in the paper is taken from:  
Welle, M.M., et al (2008) Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. *Veterinary Dermatology*, 19(6), pp.321-339

<https://doi.org/10.1111/j.1365-3164.2008.00694.x>

* 1a = One tumour confined to the dermis, without regional lymph node involvement. Without systemic signs
* 111a = Multiple dermal tumours; large infiltrating tumours with or without regional lymph node involvement. Without systemic signs

Supplementary material for the article is available at:

<https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fjvim.15806&file=JVIM_15806_Supporting+information+File+20200429.pdf>

For the Veterinary Co-operative Oncology Group criteria see:  
(2004), Veterinary co‐operative oncology group – common terminology criteria for adverse events (VCOG‐CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. *Veterinary and Comparative Oncology*, 2 (4) pp 195-213. <https://doi.org/10.1111/j.1476-5810.2004.0053b.x>